Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 94

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 94
---
s due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.  

•Consulting expenses decreased $0.1 million due to less business development activity during the three months ended September 30, 2025 compared to the three months ended September 30, 2024.    

Interest income in 2025 and 2024 related to interest earned on cash and investment balances.  

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024

Research and development expenses during the nine months ended September 30, 2025 decreased $3.2 million or 38%, compared to the nine months ended September 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.4 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.  In addition, stock-based compensation was $0.4 million lower during the current year period.

•Clinical trial expenses decreased $1.8 million primarily due to $1.3 million in lower INVINCIBLE-3 Study costs.  In March 2025, we paused new site activations and patient enrollments in the INVINCIBLE-3 Study, due to funding constraints. Prior to this pause, the trial had enrolled 23 patients.  We will continue to treat all patients enrolled in this study in cooperation with our third-party contract research organizations during this pause, and once sufficient funding is obtained, we plan to restart site activations and patient enrollment. The final costs for the IT-01 and INVINCIBLE-2 studies were also incurred during the nine months ended September 30, 2024, contributing to the decrease in clinical trial expenses compared to the nine months ended September 30, 2025.  

•Contract manufacturing costs declined by $0.6 million, as there were no manufacturing batches of INT230-6 in 2025.

General and administrative expenses during the nine months ended September 30, 2025 decreased $1.3 million or 27%, compared to the nine months ended September 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.3 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur